Navigation Links
Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
Date:3/20/2008

DENVER, March 20 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test at the American College of Cardiology (ACC) 57th Annual Scientific Session Exposition. The annual meeting takes place March 29-April 1, 2008, at the McCormick Place Convention Center in Chicago, Ill.

Corgenix representatives will be on-hand during ACC 2008 at booth 4106 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information.

AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.

Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.

"ACC 2008 represents one of the most prestigious gatherings of cardiovascular professionals in the nation and an opportunity for us to further educate the medical community about the AspirinWorks test," said Corgenix' Clinical Affairs Director Gordon Ens. "We're looking forward to demonstrating the value of more clearly understanding a patient's individual response to aspirin."

The AspirinWorks Test, which was launched in the United States in June 2007 following FDA 510(k) clearance, is now available nationwide through major medical reference laboratories, as well as direct to consumers through HealthCheckUSA (http://www.HealthCheckUSA.com).

The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin regularly.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at http://www.aspirinworks.com.

It is important that individuals taking aspirin to lower the risk of a heart attack or stroke consult a physician to determine what dose, frequency and type of aspirin is appropriate for them to achieve the most benefit with the fewest side effects.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
3. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
6. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
7. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
8. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
9. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
10. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
11. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
(Date:12/2/2016)... RICHMOND, BC , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader ... Test, to Kenya,s Pharmaceutical Association members. (Photo: ... ... , , ... Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
Breaking Biology Technology:
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):